The recall involves one lot (SAB06761A) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes, with expiration date of April 2023 and date of manufacture of May 26, 2021.

Enoxaparin sodium injection is a low molecular weight heparin indicated for the prophylaxis of deep vein thrombosis (DVT), treatment of acute DVT with or without pulmonary embolism (PE ...

Syringe marking errors, which can lead to incorrect dosing, caused a recall of Enoxaparin Sodium Injection, a generic version of blood clot medication Lovenox.

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...

Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder.

Enoxaparin Sodium Injection, USP is contraindicated in patients with active major bleeding, history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of ...

Techdow USA’s Enoxaparin Sodium (Preservative Free) Prefilled Syringes are supplied in 10-pack single-dose for subcutaneous use.

The FDA has approved the first generic formulation of enoxaparin sodium injection, a low-molecular-weight heparin product used for multiple indications, including the prevention of DVT.

The Company plans to launch Enoxaparin MDV in Q2. According to IQVIA, annual U.S sales for year ended December 31, 2018 for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) MDV was ~$11M.